First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
The company has entered into a three-year Deferred Prosecution Agreement
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Eris Lifesciences enters into term loan agreement with Citi Bank
Subscribe To Our Newsletter & Stay Updated
